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Abstract 
Background: Cerebral evoked potentials (CEP) induced by colorectal distension (CRD) in 
conscious rats provides a novel method in studies of visceral sensitivity. The aim of this study 
was to explore the pharmacological effect on CEP of compounds known to reduce the 
visceromotor response to CRD. 
Methods: Epidural electrodes were chronically implanted in eight female Sprague-Dawley 
rats. Evoked potentials were elicited by colorectal rapid balloon distensions (100 ms, 80 
mmHg) and the effect of WIN55 (cannabinoid CB receptor agonist), clonidine (adrenergic α2 
receptor agonist), MPEP (mGluR5 receptor antagonist), pregabalin (ligand of α2δ subunits in 
voltage-gated calcium channels) and baclofen (GABA-B receptor agonist) on amplitudes and 
latency of CEP were determined. 
Results: WIN55 (0.1 µmol kg-1), clonidine (0.05 µmol kg-1), MPEP (10 µmol kg-1) and 
pregabalin (200 µmol kg-1) caused a significant, p<0.05, reduction of the N2 to P2 peak-to-
peak amplitude by 23 ±8%, 25 ±8%, 39 ±5%, and 47 ±6% respectively. Baclofen (9 µmol kg-
1) induced a prolongation of the N2 peak latency of 18 ±4% but had no significant effect on 
the amplitudes. 
Conclusion: The obtained results suggest that MPEP, WIN55, clonidine, and pregabalin 
reduce visceral nociceptive input to the brain, whereas the lack of effect of baclofen on CRD 
evoked CEP amplitudes suggest that the effect on VMR is not due to a direct analgesic effect.  
Brain responses to colorectal distension provide a useful tool to evaluate pharmacological 
effects in rats and may serve as a valuable preclinica  model for understanding 
pharmacological mechanisms related to visceral sensitivity. 
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List of abbreviations: 
CB1:  Cannabinoid receptor 1 
CEP:  Cerebral evoked potential 
CRD:  Colorectal distension 
GABAB:  γ-aminobutyric acid B receptor 
IBS:  Irritable bowel syndrome 
ICC:  Intra-class correlation coefficients  
MPEP:  (2-methyl-6-(phenylethynyl)-pyridine) hydrochloride  
VMR:  Visceromotor response 
WIN55:  WIN55,212-2 [[(R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-
methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenyl-methanone], 
mesylate form] 
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1 Introduction 
Colorectal distension (CRD) has been used to study experimental visceral sensitivity in both 
human and animals (1-6). In human studies, sensory perception is commonly determined by 
the use of a subjective visual analogue scale (2,7). In contrast, most animal studies use 
contractions of the abdominal musculature caused by CRD, the so-called visceromotor 
response (VMR), as a surrogate marker for the evoked sensation (8-10). The VMR is 
considered a valid indirect marker of visceral sensation in rodents, and the model has been 
widely used in pharmacological studies assessing potential analgesic effects (5,11). Previous 
pharmacological studies have shown that the VMR to CRD is reduced by the metabotropic 
glutamate receptor 5 (mGluR5) antagonist MPEP, the γ-aminobutyric acid B (GABAB) 
receptor agonist baclofen, the cannabinoid receptor 1 (CB1) agonist WIN55, the α-
adrenoceptor agonist clonidine,  and the α2-δ ligand pregabalin (8,12-15). However, since the 
VMR response is abolished in spinalized but not in decerebrated animals, the underlying 
mechanisms mainly reflect a reflex pathway occurring in the lower brain stem and spinal cord 
(5,16,17). Therefore, the VMR model does not assess the upraspinal response to visceral 
stimulation. An alternative method to assess the supraspinal response is to record event-
related cortical evoked potentials (CEPs). In humans, CEPs have been recorded in response to 
mechanical and electrical stimulation of the rectum o objectively study and assess the brain 
response in comparison to subjective feedback (6,18-20). Rothstein et al. showed a correlation 
between CEP amplitude and stimulation intensities as well as a correlation to the subjective 
evaluation (2). We have previously successfully studied CEPs in response to CRD in 
conscious rats (21). This model showed a correlation between stimulus intensity and 
amplitude of CEPs and revealed diminished amplitudes in response to CRD when the local 
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anaesthetic lidocaine was administered rectally, indicating that interfering with peripheral 
sensory signaling alters supraspinal responses. Furthermore, we recently showed the 
translational potential of CEPs induced by CRD, by demonstrating that CEPs with similar 
morphology can be induced in both rats and humans (6).  
Conceivably, the anatomy of the CRD-evoked VMR (spinal/lower brain stem) may differ 
from pathways involved in CRD-evoked CEPs (supraspinal). The aim of the current study 
was to explore the effect of selected pharmacological agents, that have previously been shown 
to reduce the VMR to CRD, on the CRD-evoked CEPs in the novel model.  
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2 Material and Methods 
2.1 Animals: 
Eight female Sprague-Dawley rats (Harlan Laboratories, Venray, The Netherlands), weighing 
250-300 g were used in the study. The rats were allowed to acclimatize in the animal facility 
for at least one week after arrival and were group-housed in an enriched environment with 
free access to food (Standard pellets, R3, Lactamin, Kimstad, Sweden) and water on a 12:12 h 
light-dark cycle. The estrous stage of the rats was not accounted for in the current study. 
 All experiments were approved by the local animal ethics review committee in Gothenburg, 
Sweden (17-12-2008, 403-2008), and conducted at AstraZeneca, Mölndal, Sweden. All 
animal experiments comply with the ARRIVE guidelines and are carried out in 
accordance EU Directive 2010/63/EU for animal experim nts. 
 
2.2 Surgical preparation: 
The surgical approach to implant the recording electrodes has previously been described by 
our group (6, 21). Implantation of skull electrodes and positioning of an abdominal connector 
was done during anesthesia. From the abdominal conne tor silicon-coated spiral wires were 
tunneled subcutaneously across the thorax to the incisio  on top of the head. Three electrodes 
for monopolar recordings were placed on the right side of the skull (Figure 1 A). The 
positions were selected based on experience from a previous study (21).  
The rats were housed individually in cages for up to 14 days prior to any experimental 
procedures. The rats were then group-housed and were included in studies for up to three 
months. 
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2.3 Experimental preparations 
The experimental preparation has previously described by our group (21). Rats were 
habituated to Bollmann cages, 30 min per day for 3 consecutive days prior to experiments, in 
order to reduce motion artifacts due to restraint stres . In case of intravenous administration, a 
catheter was inserted in the tail vein. A 3 cm polyeth lene balloon with a maximal diameter 
of 10 mm secured to a connecting catheter, was inserted in the rectum, with the distal end of 
the balloon 3 cm cranial to the anal verge. Animal preparations were performed during light 
isoflurane anesthesia and rats were allowed to recover from sedation in the Bollmann cages 
for at least 15 min before the start of experiments. 
 
2.4 Colorectal distension 
Colorectal distension was applied by 100 ms long pressure pulses at 80 mmHg with a random 
inter-stimulus interval of 5±2 seconds. Five periods f stimulation (S1 to S5) were recorded 
for each experiment (Figure 1 B). Each period lasted four minutes separated by a resting 
period of 6 minutes, with the exception of the resting period between S3 and S4 which lasted 
10 minutes due to administration of either compound or vehicle. The first two periods of 
stimulation (S1 and S2) served as training sessions to familiarize the rats to the nature of the 
stimulation in order to obtain a stable response and these recordings were not included in the 
analysis. The third stimulation period (S3) served as baseline. Forty-eight stimulations were 
on average recorded for each stimulation period and evoked potentials were obtained as the 
average cerebral response during each stimulation period.  
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******************* Figure 1 ******************* 
 
2.5 Compounds 
MPEP (2-methyl-6-(phenylethynyl)-pyridine) hydrochloride (AstraZeneca, Mölndal, Sweden) 
R(+)-baclofen (Sigma-RBI, Natick, MA, USA),  clonidine [N-(2,6-dichlorophenyl)-4,5-
dihydro-1H-imidazol-2-amine] (Sigma-Aldrich, St. Louis, MO, USA) and pregabalin ((S)-
(+)-3-(aminomethyl)-5-methylhexanoic acid) (AstraZeneca, Mölndal, Sweden) were 
dissolved in 0.9 % saline solution at the appropriate concentrations. WIN55,212-2 [[(R)-(+)-
[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
napthalenyl-methanone], mesylate form] (WIN55) (Tocris Biosciences, Bristol, UK) was 
dissolved in 5% ethanol:5% Solutol HS15:90% saline. 
MPEP (3, 6 and 10 µmol kg-1), baclofen (9 µmol kg-1) and WIN55 (0.1 µmol kg-1) were 
administered as intravenous bolus injections (1 mL kg-1) immediately after the third 
stimulation period. Clonidine (0.05 µmol kg-1) and pregabalin (200 µmol kg-1) were 
administered as an oral gavage (5 mL kg-1) 15 min prior to the first stimulation. Isotonic 
saline was used as vehicle control in all cases. Not all rats received all compounds, but each 
compound was given to six rats and each rat received vehicle as well as multiple compounds 
on different occasions. There was a wash out period of at least one week between 
administration of the different compounds. The sequence of drug administration was in the 
same order for all rats. The different drugs were in the following order MPEP, Baclofen, 
Clonidine, Pregabalin and WIN55. 
 
2.6 Data collection and analysis 
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The EEG was recorded by use of an in-house built amplifier (gain 10000, bandwidth 0.3 Hz – 
1 kHz) at a sampling frequency of 2000 Hz. The recodings were obtained in a dimmed room, 
and all unnecessary electrical equipment was turned off to avoid 50 Hz contamination of the 
signals. The EEG signals were filtered with a 0.3 - 200 Hz band pass filter. The signals were 
stored for further analysis using in-house developed software for EEG analysis. 
 
2.7 Cerebral evoked potentials 
The CEP waveforms consisted of a number of negative (N) and positive (P) peaks numbered 
in order of occurrence (see figure 2). In order to evaluate pharmacological effects, the most 
prominent and consistent peaks (N2 and P2) were used for analysis of latency and amplitude. 
Maximal amplitudes were recorded at the electrode 1.5 mm posterior of bregma and 1.5 mm 
lateral to the midline, and hence recordings from this electrode were used for further analysis. 
Each peak was manually identified and the amplitude and latency were determined. The 
latency (ms) of the cortical responses was measured at the peak of the distinct negative and 
positive peaks. The cortical amplitude was measured for the N2 and P2 peaks and the N2-P2 
peak-to-peak amplitude. EEG signals were analyzed in the interval 0-400 ms after 
stimulation. CEPs were generated from averaging EEGsignals recorded in each session, and 
off-line analysis of the averaged CEPs was done using customized software. 
Drug administration was not blinded during the experim nts, but data analysis was performed 
by another person, who was blinded with regard to the drug administered. 
 
2.8 Evaluation of compound efficacy 
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The effects of intravenously administrated drugs were determined as the difference in 
response (latency and amplitude) between baseline (S3) and stimulation period 5 (S5). 
Compound and vehicle induced changes in brain responses were compared to test 
pharmacological efficacy. Effects of orally administered drugs were determined by comparing 
the response during stimulation period 3 (S3), with baseline (S3) recordings from vehicle 
administration, since no baseline recordings before oral administration were done. 
 
2.9 Statistical analysis 
All data are represented as mean ± standard error of mean (SEM). Repeated measurement 
ANOVA was used to assess the effect of the different drugs using SAS software version 9.1 
(SAS Institute Inc., Cary, NC, USA). P-values below 0.05 were considered as statistically 
significant. To evaluate the reproducibility intra-class correlation coefficients (ICC) were 
calculated. ICC-values describe the variation within t e individual rat in response to repeated 
stimulations compared to the variation between rats. Previously acceptable level of ICC has 
been set to ≥0.6 (22-25). 
 
3 Results 
Cerebral evoked potentials to mechanical distension at 80 mmHg were successfully recorded 
in all eight rats, and no adverse reactions were obs rved. The CEPs had a pattern consisting of 
three main peaks labeled P1, N2 and P2 (Figure 2). As the N2-P2 complex was the most 
reproducible response across all animals, it was used to evaluate compound efficacy in the 
present study. 
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******************* Figure 2 ******************* 
******************* Table I ******************* 
 
Cerebral evoked potentials 
Administration of vehicle caused no significant differences in neither latency nor amplitude 
(all p-values >0.2, Table I and Figure 2). Both latencies and amplitudes had high ICC values, 
indicating that each rat produce a similar CEP in response to mechanical distension at 80 
mmHg before and after administration of vehicle (all ICC values ≥0.97).  
 
******************* Figure 3 ******************* 
 
     MPEP caused a dose related reduction of the N2-P2 amplitude (Figure 3). The doses of 3, 
6 and 10 µmol kg-1 MPEP resulted in statistically significant reductions of 11%, 19% and 
39%, respectively (p=0.01, p=0.02, and p=0.002, respectively, see Table II). The largest effect 
of MPEP was on the P2 component. The latency was not ignificantly affected by any of the 
MPEP doses. 
 
******************* Table II ******************* 
 
     Baclofen (9 µmol kg-1) had no significant effect on the amplitude of any component, but 
caused a significant increase in latency to N2 (Table II, Figure 3). Latency to N2 was 
increased by 8.8 ± 2ms, corresponding to 18 ±4% (p=0.01). Latency to P2 was not affected. 
       The cannabinoid receptor agonist WIN55 (0.1 µmol kg-1) caused a significant reduction 
of the amplitude. The effect was significant at both N2 and N2-P2, reducing the amplitude by 
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29% and 23%, respectively (p=0.006 and p=0.046, respectively, see Table II and Figure 3). 
There was no significant effect on the latencies.  
     Clonidine (0.05 µmol kg-1) caused a statistical significant reduction of amplitude on the P2 
component and the N2-P2 amplitude (p=0.048 and p=0.048, respectively, see Table III, 
Figure 3). The P2 component was reduced by 29%. The effect on the latency was not 
significant, but a trend towards a reduction in latency was seen for both N2 and P2 (p=0.07 
and p=0.07, respectively).  
 
******************* Table III ******************* 
 
     Pregabalin (200 µmol kg-1) significantly reduced both amplitude and latency (Table III, 
Figure 3). The amplitude of N2 and P2 was reduced approximately by the same magnitude, 
48% and 42%, respectively (p=0.01 and p=0.037, respectively). The effect on latency was 
most pronounced on the P2 component, which was reduced by 30%, whereas the N2 latency 
was reduced by 18%. 
 
4 Discussion 
In the present model we used rapid CRD at 80 mmHg to generate robust and reproducible 
CEPs. These cerebral responses and how they are affected by pharmacological compounds 
may provide additional information to the overall response of the animal to a noxious visceral 
stimulus. The typically used VMR model assesses contraction of the abdominal musculature, 
which is believed to be mediated through a brainstem loop, and hence the response probably 
does not include the supraspinal modulation of the evoked sensation (5). Therefore, 
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comparing efficacy of compounds in the VMR model with the current CEP model is of 
interest. We have previously demonstrated a close crr lation between stimulation pressure 
(between 20-80 mmHg) and the amplitudes of CEPs (21). In addition, locally administered 
lidocaine attenuated CEPs in a similar fashion as previously shown for VMRs (10,26). In the 
current study we extend these findings by investigatin  the effects of other pharmacological 
compounds known to reduce the VMR to CRD in conscious rats. 
The CRD-induced CEP consisted of a number of negative nd positive peaks numbered in 
order of occurrence in accordance with previous results (21). To obtain a robust model for 
evaluating pharmacological effects only the two most prominent and consistent peaks were 
used for analysis of latency and amplitude. It cannot be excluded that more detailed analyses 
of the full response, including all peaks, may reveal further information. 
 
The mGluR5 receptor antagonist MPEP (3, 6 and 10 umol kg-1) caused a dose-dependent 
reduction of the N2-P2 amplitude evoked by CRD by up to 39% at the highest dose. 
Interestingly, these results are strikingly similar with results from the VMR and 
cardiovascular response models, where a similar dose- ependent reduction was seen (12).  
Furthermore, it has been shown that MPEP (2.5 mg kg-1, i.p.; approximately 10 µmol kg-1) 
reduced the number of Fos-positive neurons in the spinal cord in response to i.p. injection of 
acetic acid in rats which is considered a chemical model of visceral pain (27). The results 
from the current study contributes to the description of how MPEP affects the transmission of 
noxious sensations from the viscera to the supraspin l structures. However, from the present 
and previous results, it cannot be determined, if MPEP has an effect in the periphery, at the 
spinal, at the supraspinal level, or at multiple leve s. Taken together, results from the present 
and previously studies indicate a potential analgesic ffect of MPEP against visceral pain. 
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     The dual CB1/CB2-receptor agonist WIN55 (0.1 µmol kg-1) reduced the N2-P2 peak-to-
peak amplitude by 23%. In the VMR model, WIN55 reduced the response by up to 40% and 
also reduced chemically-induced colonic hypersensitivity in rodents (14,28,29). The effects of 
WIN55 appear to be mediated via cannabinoid CB1 receptors (14). By contrast, drabinol, a 
mixed CB1/CB2 receptor agonist failed to modify visceral perception to rectal distension in 
healthy volunteers and IBS patients (Klooker et al., 2011). Hence, the effects of cannabinoids 
on visceral pain have not yet been demonstrated to translate from rodents to man. 
     The α-adreneceptor agonist clonidine (0.05 µmol kg-1) reduced the N2-P2 peak-to-peak 
amplitude by 25% in the current study. In the VMR model, clonidine (0.20 µmol kg-1) 
reduced the abdominal contractions by 35% and also reduced heart rate and blood pressure 
increases in response to CRD  (15). These results are in line with the findings from the current 
study. A potential analgesic effect of clonidine on visceral pain has also been shown after 
intrathecal administration in rats (30). Interestingly, and important from a translational point 
of view, clonidine reduced pain responses to CRD in ma  and symptoms in patients suffering 
from irritable bowel syndrome (IBS), thereby implying that the current and previous models 
may have some predictive value for this pharmacological compound (31-34).  
     Pregabalin (200 µmol kg-1 p.o.) caused a reduction of both latency and amplitude of the 
CEPs, reducing the N2-P2 peak-to-peak amplitude by 47% and the latency by 30%. 
Pregabalin has demonstrated efficacy in the VMR model, reducing the response by 27% to 
72%, together with a reduction in the CRD induced autonomic responses (8,9,35,36). A 
possible analgesic effect of pregabalin has also been shown in colonic hyperalgesia, where it 
reduced the number of Fos-positive neurons in response to CRD (9,10). In healthy humans, 
pregabalin (200 mg p.o.) caused a 25% reduction of gas and pain sensation ratings in response 
to colonic balloon distension although the sensation threshold was not affected (37). In 
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hypersensitive IBS patients, pregabalin increased th  pain threshold and appeared to 
normalize rather than desensitize the perception of rectal distension in hypersensitive patients 
(38). Thus, results from the current study, together with previous results from CRD-evoked 
VMRs and autonomic responses, indicate that these models predict the analgesic effect of 
pregabalin in humans.  
The present experiments show that the agents MPEP, WIN55, clonidine and pregabalin have 
pronounced effects on the N2-P2 peak-to-peak amplitude of the CEPs. As discussed above, 
these effects are consistent with results from experiments using the VMR model or when 
monitoring cardiovascular autonomic responses. Thus, t e current study re-enforces previous 
findings suggesting that the compounds are effectiv in reducing responses to visceral 
nociceptive stimuli. Reassuringly, the current model detects central efficacy of clonidine and 
pregabalin, two agents displaying effects on CRD-evok d visceral sensations in man and 
seem to reduce symptoms in IBS patients. 
In contrast to the confirmatory results discussed so far, the results with baclofen in the current 
study failed to support previous findings. Baclofen (9 µmol kg-1) did not reduce the CEP 
amplitudes, while previous studies using the VMR model and using similar doses of baclofen 
have shown increased thresholds to colorectal pressur  and a dose-dependent reduction of the 
abdominal contraction suggesting analgesic effects with baclofen (13). Moreover, the possible 
analgesic effect is supported by experiments showing that intrathecal administrated baclofen 
reduced VMR and autonomic responses to CRD (39,40). The lack of effect in the present 
model does not exclude an analgesic effect of baclofen, as the CEP is not a pain specific 
measurement (see later in the discussion). The discrepancy between previously and the 
present study could add information regarding the parmacological effect of baclofen, with 
respect to the levels where it exerts the analgesic effe t. 
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 It could also be speculated that part of the effect s en in the VMR model is a result of the 
known muscle relaxing effect of baclofen, rather than an analgesic-like effect. However, in 
previous experiments colorectal compliance and gross motor coordination were not affected 
by baclofen at the doses used (13,41). 
Although we failed to demonstrate a clear effect of baclofen on CEP amplitudes, baclofen did 
significantly increase the N2 latency by 18%. A change in latency is difficult to interpret, as it 
can be affected by several factors. Changes in compliance or synaptic transmission can affect 
latency, but also amplitude changes of specific comp nents can appear as changes in latency 
of CEPs (42). From the present data, it was not possible to conclude, why baclofen affected 
latency or why pregabalin actually shortened latency.  
From previous experiments, it has been shown, that CRD at a pressure of 20 mmHg, which is 
not considered noxious, can elicit a CEP (21). Thus, CRD-induced CEPs are not believed to 
reflect pain per se, but rather a measurement of the visceral sensatio. Hence, the 
pharmacological effects on CRD induced CEP may not necessarily reflect analgesia, but 
rather a change in the sensation evoked by visceral stimulation.  
 
A potential confounding factor could be the possible pharmacologically induced sedation, 
which could affect the obtained CEP. Due to the experimental setup, where the rats were 
placed in a Bollmann cage, evaluation of behavior during the experiment was limited. Effects 
on behavior have, however, not been reported from previous studies where the same drugs in 
similar doses were administered (43-47). Furthermore, there were no signs of sedation in the 
obtained EEG. MPEP, clonidine and pregabalin exhibit, however, anxiolytic-like properties in 
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rodents which could affect the sensation of pain per se (43-47). An anxiolytic effect on the 
visceral sensitivity can thus not be excluded from these compounds. 
 
In the current study, no sensitization in response to r peated stimulation was apparent, which 
is in accordance with our previous study (21). This differs from studies using VMR and 
cardiovascular responses as markers of visceral sensatio . In those studies, repeated 
distensions at 80 mmHg resulted in an increasing response (5,11,12). Direct comparison 
between studies can be difficult, as different disten ion paradigms have been utilized. In the 
current study distensions only lasted 100 ms, whereas distensions in the VMR model typically 
last up to 30 seconds, which might be explain the demonstrated sensitization.  A number of 
studies have reported visceral hypersensitivity to repeated colorectal balloon distension in 
patients with IBS (49, 50, 51). Thus, it can be argued, that the present model does not reflect 
the situation seen in patients with IBS due to the CRD paradigm. 
 
A stimulation pressure of 80 mmHg been used in several previous VMR studies and proven to 
elicit a painful response in rats (5,11). We have previously shown that rapid distention with 
80 mmHg gives robust CEP (21), but no signs of painful behavior such as vocalization, 
jumping, squeaking or twist was observed. It can be discussed how clinical relevant this very 
short-lasting stimulus is. Compared to electrical stimulation often used to elicit CEP, the rapid 
mechanical stimulation is more physiological in nature, as it activated receptors in the colonic 
wall. However, is could be argued, that the very short stimulation used in the present study 
does not mimic a clinical realistic stimulus, why direct comparison to a clinical situation 
should be done with caution. 
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Previous studies have shown that response to visceral stimulation is influenced by gender (50, 
51, 52). However, controversies exist regarding this (53, 54). In the current study only female 
rats were used. Hence, it should be emphasized, that the results obtained in this study applies 
to female rats and should be generalized with caution, haven the effect of gender in mind. 
 
 
5 Conclusion 
Comparing the effects of anticipated visceral analgesic compounds on mechanically induced 
visceral pain from the present CEP experiments withresults from previous VMR models 
indicates that the two models gives rise to similar, but not identical, results. Hence, the 
findings support the rationale of using a panel of different models and endpoints when 
evaluating and predicting the preclinical effect of new visceral analgesic drugs. These 
findings contribute to a more complete assessment and hopefully a more successful 
translation of preclinical results which may be valuable in future drug development and 
prediction of efficacy in human experiments.    
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Table I: Vehicle (0.9% NaCl) had no significant effect on evoked potentials. The intraclass 
correlation coefficient (ICC) indicated that each rat produced a similar response before and 
after administration of the vehicle. All values expressed as mean ±SEM, N=8. 
 Latency (ms)  Amplitude (µV) 
 N2 P2  N2 P2 N2- 2 
 
Baseline 
 
47 ±1 113 ±4  -183 ±11 95 ±13 279 ±22 
 
Vehicle 
 
47 ±1 113 ±6  -184 ±10 104 ±15 287 ±22 
 
P-value 
 
0.76 0.93  0.93 0.23 0.39 
 
ICC-value 
 
0.97 >0.99  0.97 0.99 0.99 
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Table II: Effects of drugs administered i.v. on latency and mplitude. Changes are calculated 
as the difference between the response at baseline and after the administration of drug. P-
values are calculated between vehicle and drug experiments. All values are expressed as mean 
±SEM (p-value), N=6. 
 
 
Drug Dose (µmol 
kg-1) 
Latency change (%)  Amplitude change (%) 
N2 P2  N2 P2 N2-P2 
 
MPEP 
 
3 
3 ±2%  
(0.50) 
3 ±1% 
(0.10) 
 -13 ±3% 
(0.001) 
-5 ±2%  
(0.39) 
-11 ±1% 
(0.01) 
 
MPEP 
 
6 
-1 ±2% 
(0.57) 
-2 ±1% 
(0.56) 
 -11 ±5% 
(0.11) 
-33 ±5% 
(0.01) 
-19 ±4% 
(0.02) 
 
MPEP 
 
10 
-3 ±11% 
(0.62) 
2 ±3% 
(0.52) 
 -29 ±4% 
(0.004) 
-61 ±4% 
(0.002) 
-39 ±5% 
(0.002) 
 
Baclofen 
 
9 
18 ±4%  
(0.008) 
3 ±1% 
(0.34) 
 -12 ±3% 
(0.10) 
-1 ±12% 
(0.85) 
-9 ±3% 
(0.07) 
 
WIN55 
 
0.1 
-2 ±8% 
(0.76) 
-8 ±10% 
(0.52) 
 -29 ±5% 
(0.006) 
-7 ±20% 
(0.69) 
-23 ±8% 
(0.046) 
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Table III: Effects of drugs administered p.o. on latency and mplitude.  Latency and 
amplitude changes are the difference in response between stimulation period 3 from vehicle 
and drug experiments, relative to the vehicle respon e. All values are expressed as mean 
±SEM (p-value), N=6. 
Drug 
Dose (µmol 
kg-1) 
Latency change (%)  Amplitude change (%) 
N2 P2  N2 P2 N2-P2 
Clonidine 0.05 
-4 ±2% 
(0.07) 
 
-13 ±5% 
(0.07) 
 -21 ±11% 
(0.09) 
-29 ±11% 
(0.048) 
-25 ±8% 
(0.048) 
Pregabalin 200 
-18 ±3% 
(0.011) 
-30 ±5% 
(0.007) 
 -48 ±7% 
(0.010) 
-43 ±14% 
(0.037) 
-47 ±6% 
(0.002) 
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Legend: 
Figure 1: A: Position of skull electrodes. Three electrodes were placed 1.5 mm lateral to the 
sagittal line with the most anterior electrode 1.5 mm anterior to bregma. The following 
electrodes were separated by 3 mm. The reference ele trode was placed 2 mm posterior to 
lambda. B: Stimulation protocol. Colorectal distension was done by giving 100 ms long 
pressure pulses at 80 mmHg with an inter-stimulus-interval of 5 ±2 s. Five periods of 
stimulation were recorded for each experiments. Stimulation period 3 and 4 were separated by 
10 minutes due to administration of either drug or vehicle. All other stimulation periods were 
separated by 6 minutes. 
 
Figure 2: Effect of vehicle (0.9% NaCl) on evoked potentials. The depicted evoked potentials 
are a representative example form one rat. The diffrent components are labelled, but only the 
most stable and pronounced peaks (N2 and P2) are used to evaluate the evoked response. 
When averaging the response from all rats, the CEP appears smoother and small peaks are no 
longer apparent. 
 
Figure 3: Effect of drugs on mechanical evoked responses. Solid black lines represent the 
pre-drug response (S3) and gray dashed lines represent the response after administration of 
drugs (S5). MPEP shows a dose dependant effect, whereas baclofen had on significant effect 
on amplitude, but increased latency to the first negative peak. WIN55 caused a reduction of 
the amplitude. Orally administrated clonidine and pregabalin caused a reduction of the 
amplitude. Evoked potentials represent grand mean average based on recordings from all rats, 
n=6. 
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Pharmacological modulation of colorectal distension evoked potentials in 
conscious rats 
 
Highlights: (3-5 bullet points, <85 words) 
• MPEP, WIN55, clonidine, and pregabalin reduce visceral nociceptive input to the 
brain. 
• The obtained results suggest that the effect of baclofen on CRD-induced VMR is 
through a different mechanism than used by MPEP, WIN55, clonidine, and 
pregabalin. 
• Brain responses to colorectal distension provide a useful tool to evaluate the 
pharmacological effect in rats and may serve as a valuable model for evaluating and 
predicting the preclinical effect of visceral analgesic drugs. 
 
